

Biocon retains economic interest in global commercialization of Hulio

08 May 2019 | News

Will gain a share of profits from Global Markets



Pharma major Biocon retains economic interest in global commercialisation of Hulio in-licensed by Mylan.

“Following the successful approval and European launch of Hulio®, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets,” stated the spokesperson of Biocon.

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets.

The company said that, “Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.”